Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02652884
Other study ID # 2627
Secondary ID
Status Recruiting
Phase Phase 4
First received January 5, 2016
Last updated April 4, 2016
Start date January 2016
Est. completion date December 2017

Study information

Verified date January 2016
Source Hospital Italiano de Buenos Aires
Contact Diego H Giunta, MD
Email diego.giunta@hospitalitaliano.org.ar
Is FDA regulated No
Health authority Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Study type Interventional

Clinical Trial Summary

The incidence of thyroid cancer (TC) has increased exponentially worldwide. The increase in diagnosed cases brings about an increase in the number of surgeries performed on the thyroid gland, especially total thyroidectomy (TT), given that at present is still the gold standard of treatment.

Transient postoperative hypoparathyroidism (HPT) is one of the most frequent complications, with an incidence of between 10 and 46% according to different sources. HPT involves longer hospital stay, serial measurements of blood glucose, treatment with calcium and vitamin D (with potential risk of hypercalcemia) and therefore an increase in terms of the costs of the health system.

While the investigators know the analgesic, anti-inflammatory, immunomodulatory and anti emetic of corticosteroids in thyroid surgery, the literature available to date is discordant in the use of steroid and its interaction with the HPT making clear the need for randomized clinical trials specific to analyze these variables more accurately.

As inflammation and edema constitute a proposed surgical manipulation in the pathogenesis of HPT component, investigators decided t conduct a prospective randomized, triple-blind, in order to assess the potential benefits of the most common postoperative complication reported in TT.

Our primary objective is to evaluate the safety and efficacy of single-dose corticosteroids deposit immediately postintubation in preventing the development of transient hypoparathyroidism (PTH, serum calcium and symptoms) in patients after TT.


Description:

Triple-blind randomized clinical trial


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date December 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- adult

- thyroidectomy postoperative

- prepaid affiliate patients

Exclusion Criteria:

- allergy

- CKD

- idiophatic thrombocytopenic purpura

- hyperthyroidism

- chronic use of corticoids

- no follicular cancer, nonpapillary

- refusal to participate

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
phosphate and betamethasone acetate, 2 mL.
single dose of intramuscular depot corticosteroid
saline 0.9% NaCl
single dose of intramuscular placebo

Locations

Country Name City State
Argentina Hospital Italiano de Buenos Aires Ciudad Autonoma de Buenos Aires

Sponsors (1)

Lead Sponsor Collaborator
Hospital Italiano de Buenos Aires

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative Hypocalcemia Serial postoperative blood samples will be made to detect hypocalcemia (defined as <8,5 mg/dL)
at 1 hour postoperative from skin closure,
at 6 hours after surgery
24 hours
72 hours
3 days Yes
Secondary Related Adverse Events Any negative effects of corticosteroids will be also recorded in the postoperative and during 30 days follow up after surgery.
Major side effects associated with glucocorticoid therapy are:
Gastrointestinal (Gastritis, Peptic ulcer disease, Pancreatitis, Steatohepatitis, Visceral perforation) Dermatologic and soft tissue (Skin thinning and purpura) Cardiovascular (Arrhythmias, Hypertension, Hypotension)
30 days Yes